The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Immunotherapy in colorectal cancer: current achievements and future perspective
Open accessAbstract
Following dramatic success in many types of advanced solid tumors, interest in immunotherapy for the treatment of colorectal cancer (CRC) is increasingly growing. Given the compelling long-term durable remission, two programmed cell death 1 (PD-1)-blocking antibodies, pembrolizumab and nivolumab (with or without Ipilimumab), have been approved for the treatment of patients with metastatic colorectal cancer (mCRC) that is mismatch-repair-deficient and microsatellite instability-high (dMMR-MSI-H). Practice-changing results of several randomized controlled trials to move immunotherapy into the first-line treatment for MSI-H metastasis cancer and earlier stage were reported successively in the past 2 years. Besides, new intriguing advances to expand the efficacy of immunotherapy to mCRC that is mismatch-repair-proficient and low microsatellite instability (pMMR-MSI-L) demonstrated the potential benefits for the vast majority of mCRC cases. Great attention is also paid to the advances in cancer vaccines and adoptive cell therapy (ACT). In this review, we summarize the above progresses, and also highlight the current predictive biomarkers of responsiveness in immunotherapy with broad clinical utility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 2×
“Gut microbiota have large effect on the efficacy of immunotherapies in multiple cancers, and the composition of the intestinal microbiome could be a potential predictor of the efficacy of ICIs [82-85].”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 2×
“Gut microbiota have large effect on the efficacy of immunotherapies in multiple cancers, and the composition of the intestinal microbiome could be a potential predictor of the efficacy of ICIs [82-85].”
BackgroundApproaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075
Edwards, B. K., Ward, E., Kohler, B. A., Eheman, C., Zauber, A. G., Anderson, R. N., Jemal, A., Schymura, M. J., Lansdorp‐Vogelaar, I., Seeff, L. C., et al. (2010) · Cancer · doi:10.1002/cncr.24760 · Cited by 2,002
Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
Landon, M., Saam, J., Brown, K. L., Moyes, K., Evans, B., & Wenstrup, R. (2015) · Oncology · doi:10.1159/000430097 · Cited by 1,939
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Mechanisms and functions of DNA mismatch repair
Li, G.-M. (2008) · Cell Research · doi:10.1038/cr.2007.115 · Cited by 1,487
Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Self-citationCancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,359
Hammarström, S. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0119 · Cited by 1,300
Guanylyl Cyclases and Signaling by Cyclic GMP
Lucas, K. A., Pitari, G. M., Kazerounian, S., Ruiz-Stewart, I., Park, J., Schulz, S., Chepenik, K. P., & Waldman, S. A. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01457-1 · Cited by 1,224
Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure
Tomlinson, J. S., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kornprat, P., Gonen, M., Kemeny, N., Brennan, M. F., Blumgart, L. H., & D'Angelica, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0833 · Cited by 1,187
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
The CORGI Consortium, Palles, C., The WGS500 Consortium, Cazier, J.-B., Howarth, K. M., Domingo, E., Jones, A. M., Broderick, P., Kemp, Z., Spain, S. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2503 · Cited by 997
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890 · cited 1×
“Recently, encouraging anti-tumor activity from the combination therapy of regorafenib and nivolumab was further confirmed [64].”
BackgroundInflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
Simmonds, P. C., Primrose, J. N., Colquitt, J. L., Garden, O. J., Poston, G. J., & Rees, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603033 · Cited by 858
Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D. M., Sieber, O., & Desai, J. (2011) · Cancer · doi:10.1002/cncr.26086 · Cited by 797
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772
Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713
Sargent, D., Sobrero, A., Grothey, A., O'Connell, M. J., Buyse, M., Andre, T., Zheng, Y., Green, E., Labianca, R., O'Callaghan, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5362 · Cited by 666
Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding
Salih, H. R., Rammensee, H.-G., & Steinle, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4098 · Cited by 643
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30027-0 · Cited by 577
PD-1 blockade in tumors with mismatch repair deficiency.
Le, D. T., Uram, J. N., Wang, H., Bartlett, B., Kemberling, H., Eyring, A., Skora, A., Azad, N. S., Laheru, D. A., Donehower, R. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.lba100 · Cited by 565
Yeast DNA Polymerase ε Participates in Leading-Strand DNA Replication
Pursell, Z. F., Isoz, I., Lundström, E.-B., Johansson, E., & Kunkel, T. A. (2007) · Science · doi:10.1126/science.1144067 · Cited by 563
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Yarchoan, M., Albacker, L. A., Hopkins, A. C., Montesion, M., Murugesan, K., Vithayathil, T. T., Zaidi, N., Azad, N. S., Laheru, D. A., Frampton, G. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126908 · Cited by 545
Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma
Smyrk, T. C., Watson, P., Kaul, K., & Lynch, H. T. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12<2417::aid-cncr1276>3.0.co;2-u · Cited by 522
Histopathological Identification of Colon Cancer with Microsatellite Instability
Alexander, J., Watanabe, T., Wu, T.-T., Rashid, A., Li, S., & Hamilton, S. R. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63994-6 · Cited by 511
Dolcetti, R., Viel, A., Doglioni, C., Russo, A., Guidoboni, M., Capozzi, E., Vecchiato, N., Macrì, E., Fornasarig, M., & Boiocchi, M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65436-3 · Cited by 480
Wang, F., Zhao, Q., Wang, Y.-N., Jin, Y., He, M.-M., Liu, Z.-X., & Xu, R.-H. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2963 · Cited by 436
Katz, S. C., Burga, R. A., McCormack, E., Wang, L. J., Mooring, W., Point, G. R., Khare, P. D., Thorn, M., Ma, Q., Stainken, B. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1421 · Cited by 394
Chen, E. X., Jonker, D. J., Loree, J. M., Kennecke, H. F., Berry, S. R., Couture, F., Ahmad, C. E., Goffin, J. R., Kavan, P., Harb, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0910 · Cited by 392
A panoply of errors: polymerase proofreading domain mutations in cancer
Rayner, E., van Gool, I. C., Palles, C., Kearsey, S. E., Bosse, T., Tomlinson, I., & Church, D. N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.12 · Cited by 373
Samson, A., Scott, K. J., Taggart, D., West, E. J., Wilson, E., Nuovo, G. J., Thomson, S., Corns, R., Mathew, R. K., Fuller, M. J., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7577 · Cited by 373
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Fancello, L., Gandini, S., Pelicci, P. G., & Mazzarella, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0647-4 · Cited by 310
Domingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308
Bourgeois-Daigneault, M.-C., Roy, D. G., Aitken, A. S., El Sayes, N., Martin, N. T., Varette, O., Falls, T., St-Germain, L. E., Pelin, A., Lichty, B. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1641 · Cited by 293
Carrithers, S. L., Barber, M. T., Biswas, S., Parkinson, S. J., Park, P. K., Goldstein, S. D., & Waldman, S. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14827 · Cited by 207
Andre, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.18_suppl.lba4 · Cited by 194
Prognostic Significance of Tumor-Infiltrating Lymphocytes for Patients With Colorectal Cancer
Lee, J. H. (2012) · Archives of Surgery · doi:10.1001/archsurg.2012.35 · Cited by 176
Tabernero, J., Melero, I., Ros, W., Argiles, G., Marabelle, A., Rodriguez-Ruiz, M. E., Albanell, J., Calvo, E., Moreno, V., Cleary, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3002 · Cited by 170
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 165
Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
Bendell, J. C., Kim, T. W., Goh, B. C., Wallin, J., Oh, D.-Y., Han, S.-W., Lee, C. B., Hellmann, M. D., Desai, J., Lewin, J. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3502 · Cited by 162
Zaanan, A., Shi, Q., Taı̈eb, J., Alberts, S. R., Meyers, J. P., Smyrk, T. C., Julié, C., Zawadi, A., Tabernero, J. M., Mini, E., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2899 · Cited by 144
Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., & Salih, H. R. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0167-1 · Cited by 140
Role for the Membrane Receptor Guanylyl Cyclase-C in Attention Deficiency and Hyperactive Behavior
Gong, R., Ding, C., Hu, J., Lu, Y., Liu, F., Mann, E. A., Xu, F., Cohen, M. B., & Luo, M. (2011) · Science · doi:10.1126/science.1207675 · Cited by 124
Self-citationProgrammed death-1 blockade in mismatch repair deficient colorectal cancer.
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Azad, N. S., Laheru, D. A., Donehower, R. C., Crocenzi, T. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.103 · Cited by 106
Bendell, J. C., Powderly, J. D., Lieu, C. H., Eckhardt, S. G., Hurwitz, H. I., Höchster, H. S., Murphy, J. E., Funke, R. P., Rossi, C., Wallin, J. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.704 · Cited by 101
Rosen, L. S., LoRusso, P. M., Ma, W. W., Goldman, J. W., Weise, A. M., Colevas, A. D., Adjei, A. A., Yazji, S., Shen, A., Johnston, S. H., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0374-3 · Cited by 92
Yarchoan, M. M., Huang, C., Zhu, Q., Ferguson, A. K., Durham, J. N., Anders, R. A., Thompson, E. D., Rozich, N., Thomas, D. L., Nauroth, J. M., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2763 · Cited by 91
Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load
Li, H., Cuevas, I., Zhang, M., Lu, C., Alam, M. M., Fu, Y., You, M., Akbay, E. A., Zhang, H., & Castrillón, D. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122095 · Cited by 80
Segal, N. H., Kemeny, N. E., Cercek, A., Reidy‐Lagunes, D. L., Raasch, P. J., Warren, P., Hrabovsky, A. E., Campbell, N. M., Shia, J., Goodman, K. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3539 · Cited by 79
[Colorectal cancer screening].
Rj, L., & van Bochov, A. (2009) · PubMed · Cited by 77
Overman, M. J., Lonardi, S., Leone, F., McDermott, R., Morse, M. A., Wong, K. Y. M., Neyns, B., Leach, J. L., Alfonso, P., Lee, J. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.519 · Cited by 73
Yuki, S., Bando, H., Tsukada, Y., Inamori, K., Komatsu, Y., Homma, S., Uemura, M., Kato, T., Kotani, D., Fukuoka, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4100 · Cited by 73
Hochster, H. S., Bendell, J. C., Cleary, J. M., Foster, P., Zhang, W., He, X., Hernandez, G., Iizuka, K., & Eckhardt, S. G. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.673 · Cited by 71
Lenz, H., Cutsem, E. V., Limón, M., Wong, K., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.019 · Cited by 71
André, T., Lonardi, S., Wong, M. K., Lenz, H., Gelsomino, F., Aglietta, M., Morse, M. A., Cutsem, E. V., McDermott, R., Hill, A. G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.553 · Cited by 70
Mathur, D., Root, A. R., Bugaj‐Gaweda, B., Bisulco, S., Tan, X., Fang, W., Kearney, J. C., Lucas, J., Guffroy, M., Golas, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3275 · Cited by 70
Hornbech, K., Ravn, J. B., & Steinbrüchel, D. A. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182287da2 · Cited by 68
Gomez‐Roca, C., Yáñez, E., Im, S., Álvarez, E. C., Senellart, H., Doherty, M., García-Corbacho, J., Lopez, J. S., Basu, B., Maurice‐Dror, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.94 · Cited by 68
Panda, A., Betigeri, A. M., Subramanian, K., Ross, J. S., Pavlick, D. C., Ali, S. M., Markowski, P. A., Silk, A. W., Kaufman, H. L., Lattime, E. C., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00146 · Cited by 67
Lakins, M. A., Koers, A., Giambalvo, R., Munoz-Olaya, J. M., Hughes, R., Goodman, E., Marshall, S., Wollerton, F., Batey, S., Gliddon, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2958 · Cited by 66
Snook, A. E., Baybutt, T. R., Xiang, B., Abraham, T. S., Flickinger, J. C., Hyslop, T., Zhan, T., Kraft, W. K., Sato, T., & Waldman, S. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0576-2 · Cited by 62
Bendell, J. C., Bang, Y., Chee, C. E., Ryan, D. P., McRee, A. J., Chow, L. Q. M., Desai, J., Wongchenko, M. J., Yan, Y., Pitcher, B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.560 · Cited by 54
Lenz, H., Ou, F., Venook, A. P., Höchster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Bertagnolli, M. M., Blanke, C. D., Zemla, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3511 · Cited by 51
Lonez, C., Verma, B., Hendlisz, A., Aftimos, P. G., Awada, A. H., Neste, E. V. D., Catala, G., Machiels, J., Piette, F., Brayer, J. B., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017075 · Cited by 50
García‐Martínez, J. M., Wang, S. V., Weishaeupl, C., Wernitznig, A., Chetta, P., Pinto, C., Ho, J., Dutcher, D. L., Gorman, P. N., Kroe‐Barrett, R., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0253 · Cited by 47
Parikh, A. R., Clark, J. W., Wo, J. Y.-L., Yeap, B. Y., Allen, J. N., Blaszkowsky, L. S., Ryan, D. P., Giantonio, B. J., Weekes, C. D., Zhu, A. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3514 · Cited by 46
Sinicrope, F. A., Ou, F., Shi, Q., Nixon, A. B., Mody, K., Levasseur, A., Dueck, A. C., Dhanarajan, A. R., Lieu, C. H., Cohen, D. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps3630 · Cited by 35
Viroimmunotherapy for Colorectal Cancer: Clinical Studies
Chaurasiya, S., & Warner, S. G. (2017) · Biomedicines · doi:10.3390/biomedicines5010011 · Cited by 28
Pinsky, P. F., & Doroudi, M. (2016) · JAMA · doi:10.1001/jama.2016.13849 · Cited by 25
Heinemann, V., Kraemer, N., Buchner, H., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Lerchenmuller, C. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3591 · Cited by 15
MEK and PD-L1 inhibition in colorectal cancer: a burning blaze turning into a flash in the pan
Sclafani, F. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30076-2 · Cited by 11
Cited by
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 373
Visual Analysis of Colorectal Cancer Immunotherapy: A Bibliometric Analysis From 2012 to 2021
Ma, L., Ma, J., Teng, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843106 · Cited by 72
Huang, F., Yang, H., Bao, W., Bin, Y., Zhou, S., Wang, M., & Lv, X. (2023) · Clinical and Translational Oncology · doi:10.1007/s12094-023-03268-5 · Cited by 6
Metadata
- Authors
- Fan, A., Wang, B., Wang, X., Nie, Y., Fan, D., Zhao, X., & Lu, Y.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2021
- Volume
- 17
- Issue
- 14
- Pages
- 3837-3849
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W3196885036
- Cited by
- 410
- References
- 94
- FWCI
- 18.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.